Plate Nº 36 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Stanford Molecule Turns a Lymphoma Driver Into a Cancer Killer
A Stanford-designed molecule called TCIP3 hijacks the lymphoma-driving protein BCL6 and turns it into a trigger for cell death, wiping out aggressive human tumors in mice within 11 days.
By Elena Vasquez4 min read718 words
In brief
- Stanford's compound TCIP3 eliminated aggressive human lymphoma tumors in mice within 11 days of twice-daily treatment.
- TCIP3 works by recruiting the acetyltransferases P300 or CBP to BCL6, flipping it from a gene silencer into an activator of cell death genes.
- The study was published October 7, 2026 in the journal Cell.
- The target disease, diffuse large B-cell lymphoma, is the most common form of non-Hodgkin lymphoma.
- The compound is not yet ready for human trials and still requires further refinement and testing in additional animal species.
Aggressive human lymphoma tumors vanished in mice within 11 days after Stanford Medicine researchers treated the animals with an experimental two-part molecule called TCIP3. The compound, described October 7 in the journal Cell, hijacks a protein that normally helps cancer cells survive and turns it into a trigger for cell death.
"We're trying to essentially fight cancer with its cause — taking the driving force of the cancer and then rewiring it to activate cell death mechanisms," said Gerald Crabtree, MD, a pathologist at Stanford and a senior author of the study.
What does the molecule target?
The work homes in on BCL6, a protein that drives diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma. In healthy immune cells, BCL6 briefly silences genes that block growth or trigger death, giving the cells time to multiply during an immune response.
Once the threat passes, other proteins modify BCL6 so it can no longer silence those genes. The extra cells then die through apoptosis, a tidy form of programmed cell death that removes unneeded cells without inflammation.
In lymphoma, BCL6 stays stuck in the "on" position. Death-related genes never switch back on, and malignant cells keep dividing.
How does TCIP3 flip BCL6 into a kill switch?
The Stanford team used an approach called chemically induced proximity: building a chemical bridge between two proteins that rarely meet in nature.
TCIP3 has two binding surfaces. One side latches onto BCL6. The other grabs either P300 or CBP, two related proteins that add chemical tags called acetyl marks to nearby proteins.
Pulling BCL6 next to P300 or CBP rewrites what BCL6 does. The acetyl marks land on BCL6 itself, stripping it of its ability to suppress death genes. The same tags loosen DNA-packaging proteins called histones, exposing those genes so they switch fully on.
Lead author Meredith Nix, a Stanford graduate student, summed up the effect in driving terms: "We're not just relieving the repression conferred by BCL6; we're also actively driving the expression of these cell death genes." She compared the difference to easing off a car's brake versus flooring the accelerator.
Why does the glue effect matter?
To probe TCIP3's potency, the team crystallized the three-part complex and shot X-rays through it. The structure showed an unexpected bonus: once TCIP3 brought BCL6 and P300 together, the two proteins also made extra contact points with each other, stabilizing the entire assembly.
That insight let the chemists stiffen the linker between TCIP3's two halves, locking in the favorable contacts. The refined version killed lymphoma cells grown in the lab at very low concentrations.
What happened in the mouse experiments?
The researchers implanted human DLBCL cells into mice and let them form tumors. Twice-daily injections of TCIP3 began once the tumors established themselves.
"By 11 days, the tumors that had been treated with TCIP3 were completely gone, whereas the tumors in the control animals remained," Nix said.
Treated mice showed no obvious toxicity. Blood tests did not reveal increased inflammation. The drug also dismantled germinal centers, clusters of fast-dividing B cells that depend heavily on BCL6 and resemble the cells that go wrong in DLBCL.
That second effect hints at uses beyond cancer. Germinal centers play a role in autoimmune diseases including rheumatoid arthritis and myasthenia gravis, and the team thinks TCIP3-like molecules could eventually be tested in those conditions too.
Could this approach reach patients?
Not anytime soon. TCIP3 needs more chemical refinement and safety testing in other animal species before any human trial can be considered, the researchers caution. They see it as a proof of concept for a broader strategy of rewiring cancer-driving proteins rather than simply blocking them.
Co-senior authors on the paper include Stanford chemical biologist Nathanael Gray, PhD, Stanford molecular physiologist Stephen Hinshaw, PhD, and Michael Green, PhD, who directs lymphoma and myeloma research at MD Anderson Cancer Center. Researchers from MD Anderson and the AI drug-discovery platform Deep Origin also contributed. Funding came from the National Institutes of Health, the Howard Hughes Medical Institute, the Mary Kay Foundation, the Williams Foundation, and several other foundations.
Crabtree and Gray are founders and scientific advisors for Shenandoah Therapeutics, which holds a Stanford license for the TCIP technology.
via med.stanford.edu (Original)
More from Elena Vasquez
Nearby plates
- New Drug CS18 Reverses Cancer Treatment Resistance in Lab Tests
- Researchers identify MEK as driver of T cell exhaustion in cancer
- Two Gatekeeper Proteins Guide Immune Cells' Risky DNA Mutations
- Why a 70-Year-Old Leukemia Drug Still Surprises Scientists
- Same-Day Chemotherapy Turns Into a Booster for Cancer Vaccines